Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
S Dulucq, FX Mahon - Cancer medicine, 2016 - Wiley Online Library
Several clinical trials have demonstrated that some patients with chronic myeloid leukemia
in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine …
in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine …
Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia
L Caldemeyer, LP Akard - Leukemia & Lymphoma, 2016 - Taylor & Francis
With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib,
bosutinib, and ponatinib, many patients with chronic myeloid leukemia in chronic phase …
bosutinib, and ponatinib, many patients with chronic myeloid leukemia in chronic phase …
[HTML][HTML] Considerations for successful treatment-free remission in chronic myeloid leukemia
SL Goldberg, M Savona, MJ Mauro - Clinical Lymphoma Myeloma and …, 2018 - Elsevier
BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with
chronic myeloid leukemia, and current studies are investigating whether some patients may …
chronic myeloid leukemia, and current studies are investigating whether some patients may …
Recommendations from a portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice
A Almeida, F Pierdomenico… - Acta Médica …, 2019 - actamedicaportuguesa.com
Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase
Inhibitors in Chronic Myeloid Leukemia Pat Page 1 NORMAS ORIENT AÇÃO Revista …
Inhibitors in Chronic Myeloid Leukemia Pat Page 1 NORMAS ORIENT AÇÃO Revista …
Vysazování inhibitorů tyrozinkináz u pacientů s chronickou myeloidní leukemií ve studiích a klinické praxi.
P Čičátková, D Žáčková - Transfusiology & Haematology …, 2020 - search.ebscohost.com
Zavedení inhibitorů tyrozinkináz dramaticky zlepšilo prognózu pacientů s chronickou
myeloidní leukemií. Očekávaná délka života pacientů při nově diagnostikovaném …
myeloidní leukemií. Očekávaná délka života pacientů při nově diagnostikovaném …
Update on the management of chronic myeloid leukemia: current best practice and future directions
A Nee, JH Lipton - Expert Opinion on Orphan Drugs, 2019 - Taylor & Francis
Introduction: Tyrosine kinase inhibitor (TKI) therapy has dramatically improved survival for
patients with chronic myeloid leukemia (CML). The focus of CML therapy is now shifting to …
patients with chronic myeloid leukemia (CML). The focus of CML therapy is now shifting to …